Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14106689 | 1.00 | PPARA (0.39) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL14106700 | 0.94 | PPARA (0.41) | PPARAKCNJ5KCNJ3PPARGEPHX2 | |
| SCHEMBL14106701 | 0.94 | PPARA (0.41) | PPARAKCNJ5KCNJ3PPARGEPHX2 | |
| SCHEMBL4834937 | 0.92 | HPGD (0.44) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL14106685 | 0.92 | HPGD (0.44) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL6476837 | 0.92 | PPARA (0.40) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL6476827 | 0.92 | PPARA (0.40) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL4830075 | 0.92 | PPARA (0.40) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL14106732 | 0.87 | FFAR1 (0.41) | PPARAKCNJ5KCNJ3PPARGFFAR1 | |
| SCHEMBL14106694 | 0.86 | PPARG (0.40) | PPARAKCNJ5KCNJ3PPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6884812-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | PPARA 383/4885KCNJ5 1618/4885KCNJ3 2151/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | PPARA 365/4885KCNJ5 1697/4885KCNJ3 2238/4885 |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, LIPA | PPARA 345/4885KCNJ5 1653/4885KCNJ3 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.